Shattuck Labs, Inc. Operating Cash Flow
Shattuck Labs, Inc. (STTK) reported Operating Cash Flow of -$23.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$10.19M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.42M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$8.49M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$8.93M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$39.88M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$60.52M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$81.23M.
- Shattuck Labs, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$94.50M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$23.61M 10-Q · filed 2026-08-11 | -$32.10M derived: sum of 3 quarters · filed 2026-08-11 | -$41.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$13.42M 10-Q · filed 2026-05-07 | -$21.91M derived: sum of 2 quarters · filed 2026-05-07 | -$30.84M derived: sum of 3 quarters · filed 2026-05-07 | -$41.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$8.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$17.42M derived: sum of 2 quarters · filed 2026-03-05 | -$27.85M derived: sum of 3 quarters · filed 2026-08-11 | -$39.88M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$8.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$19.36M derived: sum of 2 quarters · filed 2026-08-11 | -$31.39M 10-Q · filed 2025-11-06 | -$48.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$22.46M 10-Q · filed 2026-08-11 | -$39.83M derived: sum of 3 quarters · filed 2026-08-11 | -$55.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$12.03M 10-Q · filed 2026-05-07 | -$29.40M derived: sum of 2 quarters · filed 2026-05-07 | -$45.47M derived: sum of 3 quarters · filed 2026-05-07 | -$56.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$17.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$33.44M derived: sum of 2 quarters · filed 2026-03-05 | -$44.35M derived: sum of 3 quarters · filed 2026-03-05 | -$60.52M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$16.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$26.98M derived: sum of 2 quarters · filed 2025-11-06 | -$43.15M 10-Q · filed 2025-11-06 | -$62.56M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$10.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$27.08M 10-Q · filed 2025-08-14 | -$46.50M derived: sum of 3 quarters · filed 2025-08-14 | -$63.23M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$16.16M 10-Q · filed 2025-05-01 | -$35.58M derived: sum of 2 quarters · filed 2025-05-01 | -$52.31M derived: sum of 3 quarters · filed 2025-05-01 | -$70.93M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$19.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$36.15M derived: sum of 2 quarters · filed 2025-03-27 | -$54.77M derived: sum of 3 quarters · filed 2025-03-27 | -$81.23M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$16.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$35.35M derived: sum of 2 quarters · filed 2024-11-14 | -$61.81M 10-Q · filed 2024-11-14 | -$85.65M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$18.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$45.08M 10-Q · filed 2024-08-01 | -$68.92M derived: sum of 3 quarters · filed 2024-08-01 | -$96.98M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$26.46M 10-Q · filed 2024-05-02 | -$50.30M derived: sum of 2 quarters · filed 2024-05-02 | -$78.37M derived: sum of 3 quarters · filed 2024-05-02 | -$94.68M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$23.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$51.91M derived: sum of 2 quarters · filed 2024-02-29 | -$68.22M derived: sum of 3 quarters · filed 2024-02-29 | -$94.50M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$28.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$44.38M derived: sum of 2 quarters · filed 2023-11-09 | -$70.66M 10-Q · filed 2023-11-09 | -$89.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$16.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$42.59M 10-Q · filed 2023-08-10 | -$61.31M derived: sum of 3 quarters · filed 2023-08-10 | -$74.30M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$26.28M 10-Q · filed 2023-05-09 | -$44.99M derived: sum of 2 quarters · filed 2023-05-09 | -$57.99M derived: sum of 3 quarters · filed 2023-05-09 | -$72.33M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$18.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$31.71M derived: sum of 2 quarters · filed 2023-02-23 | -$46.05M derived: sum of 3 quarters · filed 2023-02-23 | -$57.12M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$12.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$27.33M derived: sum of 2 quarters · filed 2022-11-09 | -$38.40M 10-Q · filed 2022-11-09 | -$52.44M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$14.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$25.41M 10-Q · filed 2022-08-11 | -$39.45M derived: sum of 3 quarters · filed 2022-08-11 | -$50.80M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$11.07M 10-Q · filed 2022-05-12 | -$25.11M derived: sum of 2 quarters · filed 2022-05-12 | -$36.46M derived: sum of 3 quarters · filed 2022-05-12 | -$34.27M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$14.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$25.39M derived: sum of 2 quarters · filed 2022-03-15 | -$23.21M derived: sum of 3 quarters · filed 2022-03-15 | -$33.66M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$11.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$9.16M derived: sum of 2 quarters · filed 2021-11-09 | -$19.62M 10-Q · filed 2021-11-09 | -$27.24M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$8.27M 10-Q · filed 2021-08-12 | -$15.89M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$10.45M 10-Q · filed 2021-05-10 | -$18.07M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | -$7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$20.98M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$13.35M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |